Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel A Funt

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
The Oncologist|July 11, 2026
Utilizing Micro-RNA-371a-3p for Recurrence Prediction in Clinical Stage I Testicular CancerRichard S Matulewicz, Andrea Knezevic, Adam Levin, et al.
European Urology|October 3, 2018
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial CancerNick van Dijk, Samuel A Funt, Christian U Blank, et al.
Urology|January 9, 2023
Evaluation of Women With a Positive Urine Cytology and no Demonstrable Disease in the Urinary TractSherri M Donat, Yukio Sonoda, Hikmat Al-Ahmadie, et al.
The Journal of Urology|September 6, 2023
Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the RetroperitoneumRichard S Matulewicz, Nicole Benfante, Samuel A Funt, et al.
The American Journal of Cardiology|February 15, 2011
Incidence, epidemiology, and prognosis of residual pulmonary hypertension after mitral valve repair for degenerative mitral regurgitationAndrew B Goldstone, Joanna Chikwe, Sean P Pinney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2018
Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing OutRune A W van de Wetering, Stefan Sleijfer, Darren R Feldman, et al.
Investigational New Drugs|June 27, 2022
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumorsNabil Adra, David J Vaughn, Lawrence H Einhorn, et al.
Clinical Genitourinary Cancer|September 22, 2024
Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node DissectionFady Baky, Nicole Liso, Brandon Williams, et al.
The Journal of Urology|July 7, 2025
Performance characteristics of an analytic model predicting retroperitoneal lymph node dissection pathology following first-line chemotherapy for patients with metastatic non-seminomatous germ cell tumorsRichard S Matulewicz, Melissa Assel, Andrew J Vickers, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|April 20, 2023
Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot StudyMichael A Hoyt, Ashley Wei-Ting Wang, Raymond Carrillo Ceja, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
The Oncologist|July 11, 2026
Utilizing Micro-RNA-371a-3p for Recurrence Prediction in Clinical Stage I Testicular CancerRichard S Matulewicz, Andrea Knezevic, Adam Levin, et al.
European Urology|October 3, 2018
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial CancerNick van Dijk, Samuel A Funt, Christian U Blank, et al.
Urology|January 9, 2023
Evaluation of Women With a Positive Urine Cytology and no Demonstrable Disease in the Urinary TractSherri M Donat, Yukio Sonoda, Hikmat Al-Ahmadie, et al.
The Journal of Urology|September 6, 2023
Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the RetroperitoneumRichard S Matulewicz, Nicole Benfante, Samuel A Funt, et al.
The American Journal of Cardiology|February 15, 2011
Incidence, epidemiology, and prognosis of residual pulmonary hypertension after mitral valve repair for degenerative mitral regurgitationAndrew B Goldstone, Joanna Chikwe, Sean P Pinney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2018
Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing OutRune A W van de Wetering, Stefan Sleijfer, Darren R Feldman, et al.
Investigational New Drugs|June 27, 2022
A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumorsNabil Adra, David J Vaughn, Lawrence H Einhorn, et al.
Clinical Genitourinary Cancer|September 22, 2024
Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node DissectionFady Baky, Nicole Liso, Brandon Williams, et al.
The Journal of Urology|July 7, 2025
Performance characteristics of an analytic model predicting retroperitoneal lymph node dissection pathology following first-line chemotherapy for patients with metastatic non-seminomatous germ cell tumorsRichard S Matulewicz, Melissa Assel, Andrew J Vickers, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|April 20, 2023
Goal-Focused Emotion-Regulation Therapy (GET) in Young Adult Testicular Cancer Survivors: A Randomized Pilot StudyMichael A Hoyt, Ashley Wei-Ting Wang, Raymond Carrillo Ceja, et al.
Pageof 8